Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGT4859 in Cholangiocarcinoma and Advanced Solid Tumors
NCT06777316Phase 2Active, not recruiting
- Sponsor
- Cogent Biosciences
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of CGT4859 in cholangiocarcinoma (CCA) and solid tumor (2 arms), sponsored by Cogent Biosciences. Primary endpoints: Maximum Tolerated Dose at 12 months, Recommended Phase 2 Dose at 12 months and 1 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
CGT4859
03
Conditions
cholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT06777316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777316.